Oramed Pharmaceuticals PE ratio ORMP

Share price divided by earnings per share over the last twelve months, since 2015.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 21.2×; Mar 2025
6-year median: 20.5×
6-year range: 10.0× to 23.4×
Peer median: 11.3×

Oramed Pharmaceuticals' PE ratio is not a meaningful number today: net income over the last twelve months was more than twice operating income, so most of it came from below the operating line (a gain on a sale, debt written off, a tax benefit, investment income) and the low PE on it says nothing about the business.

It was last meaningful in Mar 2025, at 21.2×.

On the days it had one over the last 6 years, its median was 20.5×, from 10.0× in Jul 2024 to 23.4× in Mar 2025.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2025	21.2×	19.0×	23.4×
2024	21.5×	10.0×	22.5×
2023	n/m a value too high to mean anything
2022	n/m a value too high to mean anything
2021	n/m a value too high to mean anything
2020	10.5×	10.1×	12.3×
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	n/m a value too high to mean anything
2016	10.7×	10.7×	10.7×
2015	12.8×	11.6×	13.4×

Against its peers

Companies in Drug Manufacturers - General nearest Oramed Pharmaceuticals' size, closest first, today.

Company	PE ratio
ORMPOramed Pharmaceuticals	n/m
NATRNatures Sunshine Products	12.0×
LFVNLifevantage	14.7×
SPROSpero Therapeutics	10.1×
ARVNArvinas	45.6×
PBYIPuma Biotechnology	21.2×
IRWDIronwood Pharmaceuticals	4.5×
ZVRAZevra Therapeutics	10.5×
CRMDCorMedix	3.7×
ATNMActinium Pharmaceuticals	4.2×
COLLCollegium Pharmaceutical	18.5×
Peer median	11.3×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Oramed Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.